Company: HURA
Filing Date: 2025-06-06
Form Type: 425
Source: 0001193125-25-137145
Chunk: 19

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-06-06
Form: 425
Chunk 19
---
 adjustment pursuant to this
, the Company at its expense will promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and prepare a certificate setting forth such adjustment, including a statement of the
adjusted Exercise Price and adjusted number or type of Warrant Shares, Prefunded Warrants or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such adjustments and showing in detail
the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the Transfer Agent.

(h) . If, while this Warrant is outstanding, the Company (i) declares a dividend or any other
distribution of cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital stock of the Company or any subsidiary,
(ii) authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii) authorizes the voluntary dissolution, liquidation or winding up of the affairs of the Company,
then the Company shall deliver to the Holder a notice of such transaction at least ten (10) days prior to the applicable record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect
to such transaction; provided, however, that the failure to deliver such notice or any defect therein shall not affect the validity of the corporate action required to be described in such notice. In addition, if while this Warrant is outstanding,
the Company authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction contemplated by , other than a Fundamental Transaction under clause
(iii) of the Company shall deliver to the Holder a notice of such Fundamental Transaction at least thirty (30) days prior to the date such Fundamental Transaction is consummated. Holder agrees to
maintain any information disclosed pursuant to this in confidence until such information is publicly available, and shall comply with applicable law with respect to trading in the Company’s securities
following receipt of any such information. Notwithstanding the foregoing, no additional notice needs to be provided to the Holder in the event the information if included in a filing by the Company with the Securities and Exchange Commission.

(i) . Subject to the rules and regulations of the Principal Trading Market, the Company may at any time
during the term of this Warrant, reduce the then-current Exercise Price to